Alfred D Mahr

List of Publications by Year
in descending order

163 papers	21,801 citations	12330 69 h-index	9103 144 g-index
168 all docs	168 docs citations	168 times ranked	10761 citing authors

#	Article	IF	Citations
1	Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Annals of the Rheumatic Diseases, 2006, 66, 222-227.	0.9	1,041
2	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
3	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. New England Journal of Medicine, 2014, 371, 1771-1780.	27.0	842
4	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.9	719
5	The Five-Factor Score Revisited. Medicine (United States), 2011, 90, 19-27.	1.0	716
6	Eosinophilic granulomatosis with polyangiitis (Churgâ€Strauss): Clinical characteristics and longâ€term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis and Rheumatism, 2013, 65, 270-281.	6.7	670
7	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.9	667
8	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. New England Journal of Medicine, 2008, 359, 2790-2803.	27.0	603
9	Antineutrophil Cytoplasmic Antibodies and the Churgâ€“Strauss Syndrome. Annals of Internal Medicine, 2005, 143, 632.	3.9	592
10	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524
11	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. JAMA - Journal of the American Medical Association, 2010, 304, 2381.	7.4	524
12	Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data metaâ€analysis. Arthritis and Rheumatism, 2007, 56, 2789-2797.	6.7	521
13	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis and Rheumatism, 2010, 62, 616-626.	6.7	483
14	Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: A capture-recapture estimate. Arthritis and Rheumatism, 2004, 51, 92-99.	6.7	453
15	2018 update of the EULAR recommendations for the management of BehÃ§etâ€™s syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213225.	0.9	442
16	HLAâ€“B51/B5 and the risk of BehÃ§et's disease: A systematic review and metaâ€analysis of caseâ€“control genetic association studies. Arthritis and Rheumatism, 2009, 61, 1287-1296.	6.7	384
17	Hepatitis B Virus-Associated Polyarteritis Nodosa. Medicine (United States), 2005, 84, 313-322.	1.0	371
18	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	2.2	371

#	Article	IF	Citations
19	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.9	343
20	Presentation and Outcome of Gastrointestinal Involvement in Systemic Necrotizing Vasculitides. Medicine (United States), 2005, 84, 115-128.	1.0	332
21	Treatment of Churgâ€Strauss syndrome without poorâ€prognosis factors: A multicenter, prospective, randomized, openâ€label study of seventyâ€two patients. Arthritis and Rheumatism, 2008, 58, 586-594.	6.7	294
22	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis–a meta-analysis. Rheumatology, 2012, 51, 100-109.	1.9	285
23	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. Arthritis and Rheumatism, 2011, 63, 863-864.	6.7	244
24	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis and Rheumatism, 2007, 57, 686-693.	6.7	243
25	Diagnosis and management of Neuro-BehÃ§etâ€™s disease: international consensus recommendations. Journal of Neurology, 2014, 261, 1662-1676.	3.6	236
26	Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixtyâ€five patients. Arthritis and Rheumatism, 2003, 49, 93-100.	6.7	225
27	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Annals of the Rheumatic Diseases, 2015, 74, 177-184.	0.9	214
28	Deaths Occurring During the First Year After Treatment Onset for Polyarteritis Nodosa, Microscopic Polyangiitis, and Churg-Strauss Syndrome. Medicine (United States), 2005, 84, 323-330.	1.0	210
29	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibodyâ€“associated vasculitis: A metaâ€analysis. Arthritis Care and Research, 2010, 62, 1166-1173.	3.4	200
30	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
31	Central Nervous System Involvement in Wegener Granulomatosis. Medicine (United States), 2006, 85, 53-65.	1.0	197
32	Epidemiology of immunoglobulin A vasculitis (Henochâ€“SchÃ¶nlein). Current Opinion in Rheumatology, 2013, 25, 171-178.	4.3	194
33	Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Annals of the Rheumatic Diseases, 2008, 67, 110-116.	0.9	191
34	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Annals of the Rheumatic Diseases, 2013, 72, 1003-1010.	0.9	183
35	Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrology Dialysis Transplantation, 2015, 30, i14-i22.	0.7	183
36	'MHC-I-opathy'â€"unified concept for spondyloarthritis and BehÃ§et disease. Nature Reviews Rheumatology, 2015, 11, 731-740.	8.0	183

#	Article	IF	Citations
37	Treatment of polyarteritis nodosa and microscopic polyangiitis without poorâ€prognosis factors: A prospective randomized study of one hundred twentyâ€four patients. Arthritis and Rheumatism, 2010, 62, 1186-1197.	6.7	179
38	Relationships of HLA-B51 or B5 genotype with BehÃ§et's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology, 2012, 51, 887-900.	1.9	171
39	Populationâ€based prevalence study of BehÃ§et's disease: Differences by ethnic origin and low variation by age at immigration. Arthritis and Rheumatism, 2008, 58, 3951-3959.	6.7	170
40	Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, openâ€label study of twentyâ€two patients. Arthritis and Rheumatism, 2008, 58, 308-317.	6.7	163
41	Aortic involvement in recentâ€onset giant cell (temporal) arteritis: A caseâ€“control prospective study using helical aortic computed tomodensitometric scan. Arthritis and Rheumatism, 2008, 59, 670-676.	6.7	152
42	Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Revue De Medecine Interne, 2016, 37, 154-165.	1.0	152
43	ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrology Dialysis Transplantation, 2005, 20, 1392-1399.	0.7	150
44	Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixtyâ€Five Years or Older: Results of a Multicenter, Openâ€Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamideâ€“Based Induction Therapy. Arthritis and Rheumatology, 2015, 67, 1117-1127.	5.6	150
45	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology, 2012, 51, 460-467.	1.9	147
46	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
47	Association of Granulomatosis With Polyangiitis (Wegener's) With HLAâ€“DPB1*04 and SEMA6A Gene Variants: Evidence From Genomeâ€Wide Analysis. Arthritis and Rheumatism, 2013, 65, 2457-2468.	6.7	138
48	Predicting mortality in systemic Wegener's granulomatosis: A survival analysis based on 93 patients. Arthritis and Rheumatism, 2004, 51, 83-91.	6.7	137
49	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	5.6	130
50	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
51	Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Annals of the Rheumatic Diseases, 2011, 70, 1415-1421.	0.9	126
52	Trial of Apremilast for Oral Ulcers in BehÃ§etâ€™s Syndrome. New England Journal of Medicine, 2019, 381, 1918-1928.	27.0	125
53	Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?. Annals of the Rheumatic Diseases, 2006, 65, 826-828.	0.9	122
54	Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. Medicine (United States), 2014, 93, 340-349.	1.0	122

#	Article	IF	Citations
55	The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax, 2008, 63, 677-682.	5.6	119
56	Microscopic polyangiitis and polyarteritis nodosa: How and when do they start?. Arthritis and Rheumatism, 2003, 49, 709-715.	6.7	113
57	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss). Current Opinion in Rheumatology, 2014, 26, 16-23.	4.3	110
58	Epidemiology of Primary SjÃ¶gren's Syndrome in a French Multiracial/Multiethnic Area. Arthritis Care and Research, 2014, 66, 454-463.	3.4	107
59	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2011, 70, 704-704.	0.9	106
60	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology, 2015, 54, 471-481.	1.9	104
61	Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmunity Reviews, 2014, 13, 850-857.	5.8	101
62	Brief Report: Prevalence of Antineutrophil Cytoplasmic Antibodies in Infective Endocarditis. Arthritis and Rheumatology, 2014, 66, 1672-1677.	5.6	99
63	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. Journal of Rheumatology, 2008, 35, 1064-72.	2.0	99
64	Hypotheses on the Etiology of Antineutrophil Cytoplasmic Autoantibodyâ€“Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 237-252.	4.5	94
65	Management of major organ involvement of BehÃ§etâ€™s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology, 2018, 57, 2200-2212.	1.9	89
66	Alpha₁â€antitrypsin deficiencyâ€“related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis and Rheumatism, 2010, 62, 3760-3767.	6.7	87
67	Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Annals of the Rheumatic Diseases, 2007, 67, 1343-1346.	0.9	81
68	Epidemiology and Etiology of Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome and Goodpasture Syndrome: Vasculitides with Frequent Lung Involvement. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 264-273.	2.1	78
69	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
70	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis and Rheumatology, 2022, 74, 295-306.	5.6	78
71	Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology, 2020, 59, 1011-1020.	1.9	77
72	Incidence of IgA vasculitis in children estimated by four-source captureâ€“recapture analysis: a population-based study. Rheumatology, 2017, 56, 1358-1366.	1.9	75

#	Article	IF	Citations
73	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20736-20741.	7.1	74
74	Incidence and predictors of urotoxic adverse events in cyclophosphamideâ€treated patients with systemic necrotizing vasculitides. Arthritis and Rheumatism, 2011, 63, 1435-1445.	6.7	68
75	Exploring the variability in BehÃ§etâ€™s disease prevalence: a meta-analytical approach. Rheumatology, 2018, 57, 185-195.	1.9	66
76	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care and Research, 2011, 63, 1055-1061.	3.4	63
77	Gender-specific differences in Adamantiadesâ€“BehÃ§etâ€™s disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology, 2015, 54, 121-133.	1.9	63
78	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Medicale, 2013, 42, 1317-1330.	1.9	62
79	ANCA-associated vasculitis and malignancy: Current evidence for cause and consequence relationships. Best Practice and Research in Clinical Rheumatology, 2013, 27, 45-56.	3.3	62
80	Longitudinal Cohort Study of Patients With Birdshot Chorioretinopathy. I. Baseline Clinical Characteristics. American Journal of Ophthalmology, 2006, 141, 135-142.	3.3	60
81	Urogenital Manifestations in Wegener Granulomatosis. Medicine (United States), 2012, 91, 67-74.	1.0	56
82	Management of skin, mucosa and joint involvement of BehÃ§etâ€™s syndrome: A systematic review for update of the EULAR recommendations for the management of BehÃ§etâ€™s syndrome. Seminars in Arthritis and Rheumatism, 2019, 48, 752-762.	3.4	56
83	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open, 2019, 5, e001020.	3.8	56
84	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
85	Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 103-106.	0.9	54
86	Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology, 2016, 55, 1656-1663.	1.9	54
87	Kawasaki disease in adults: Observations in France and literature review. Autoimmunity Reviews, 2016, 15, 242-249.	5.8	54
88	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open, 2019, 5, e001003.	3.8	52
89	Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Current Opinion in Rheumatology, 2012, 24, 193-200.	4.3	51
90	Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placeboâ€controlled clinical trials. Pharmacoepidemiology and Drug Safety, 2017, 26, 731-741.	1.9	51

#	Article	IF	Citations
91	Granulomatosis with Polyangiitis (Wegener's). Journal of the American Society of Nephrology: JASN, 2011, 22, 587-588.	6.1	49
92	Limited Value of Temporal Artery Ultrasonography Examinations for Diagnosis of Giant Cell Arteritis: Analysis of 77 Subjects. Journal of Rheumatology, 2010, 37, 2326-2330.	2.0	48
93	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Autoimmunity Reviews, 2018, 17, 115-124.	5.8	48
94	Outcomes in Critically Ill Patients With Systemic Rheumatic Disease. Chest, 2015, 148, 927-935.	0.8	47
95	Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Annals of the Rheumatic Diseases, 2010, 69, 2125-2130.	0.9	45
96	Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): Blinded histologic assessment of 35 cPAN cases. Journal of the American Academy of Dermatology, 2015, 73, 1013-1020.	1.2	40
97	Serum Eosinophil Cationic Protein: A Marker of Disease Activity in Churg-Strauss Syndrome. Annals of the New York Academy of Sciences, 2007, 1107, 392-399.	3.8	38
98	Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980â€“2011). Rheumatology, 2018, 57, 1047-1055.	1.9	38
99	Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibodyâ€“associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. Rheumatology, 2015, 54, 1970-1975.	1.9	37
100	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	5.6	36
101	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	2.0	35
102	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.9	34
103	Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis. Arthritis and Rheumatism, 2008, 59, 884-891.	6.7	33
104	Metaâ€analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3463-3471.	6.7	33
105	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. Journal of Rheumatology, 2015, 42, 2465-2469.	2.0	33
106	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1933-1937.	2.0	33
107	The future of damage assessment in vasculitis. Journal of Rheumatology, 2007, 34, 1357-71.	2.0	33
108	Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology, 2019, 58, 1707-1709.	1.9	32

#	Article	IF	Citations
109	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	2.0	32
110	Scleroderma Renal Crisis, Still a Life-Threatening Complication. Annals of the New York Academy of Sciences, 2007, 1108, 249-258.	3.8	30
111	Classification and classification criteria for vasculitis. Current Opinion in Rheumatology, 2015, 27, 1-9.	4.3	30
112	French recommendations for the management of BehÃ§etâ€™s disease. Orphanet Journal of Rare Diseases, 2021, 16, 352.	2.7	27
113	Developing a Core Set of Outcome Measures for BehÃ§et Disease: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1750-1753.	2.0	25
114	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. Journal of Rheumatology, 2017, 44, 1529-1535.	2.0	25
115	Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ, The, 2022, 376, e064597.	6.0	25
116	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 2019, 46, 1198-1201.	2.0	24
117	Analysis of Wegenerâ€™s Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects. Clinical Reviews in Allergy and Immunology, 2008, 34, 65-73.	6.5	23
118	Epidemiological features of Wegener's granulomatosis and microscopic polyangiitis: two diseases or one â€˜antiâ€neutrophil cytoplasm antibodiesâ€associated vasculitisâ€™ entity?. Apmis, 2009, 117, 41-47.	2.0	23
119	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
120	Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis. Journal of Rheumatology, 2017, 44, 1039-1043.	2.0	22
121	Dietary and Nondietary Triggers of Oral Ulcer Recurrences in BehÃ§et's Disease. Arthritis Care and Research, 2017, 69, 1429-1436.	3.4	22
122	Extraocular manifestations of birdshot chorioretinopathy in 118 French patients. Presse Medicale, 2010, 39, e97-e102.	1.9	21
123	The European Vasculitis Society 2016 Meeting Report. Kidney International Reports, 2017, 2, 1018-1031.	0.8	21
124	Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era. Medicine (United States), 2017, 96, e6230.	1.0	21
125	Core Set of Domains for Outcome Measures in BehÃ§et's Syndrome. Arthritis Care and Research, 2022, 74, 691-699.	3.4	21
126	Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis. Annals of Intensive Care, 2012, 2, 31.	4.6	20

#	Article	IF	Citations
127	Long-term outcome ofÂ37Âpatients with Wegener's granulomatosis with renal involvement. Presse Medicale, 2007, 36, 771-778.	1.9	18
128	Current Status, Goals, and Research Agenda for Outcome Measures Development in BehÃ§et Syndrome: Report from OMERACT 2014. Journal of Rheumatology, 2015, 42, 2436-2441.	2.0	18
129	Nomenclature of cutaneous vasculitides â€“ German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1425-1432.	0.8	18
130	Seasonal variations in onset of Wegener's granulomatosis: increased in summer?. Journal of Rheumatology, 2006, 33, 1615-22.	2.0	18
131	Noncorticosteroid Immunosuppression LimitsÂMyocardial Damage and Contractile Dysfunction inÂEosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome). Journal of the American College of Cardiology, 2015, 65, 103-105.	2.8	17
132	Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data. Rheumatology, 2020, 59, 120-128.	1.9	17
133	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 1314-1325.	3.4	17
134	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. Seminars in Arthritis and Rheumatism, 2014, 43, 681-688.	3.4	15
135	Nomenklatur der kutanen Vaskulitiden â€“ deutschsprachige Definitionen des Dermatologischen Anhanges zur Chapel Hill Consensus Conference. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1425-1433.	0.8	15
136	Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records. Lancet Rheumatology, The, 2020, 2, e774-e778.	3.9	14
137	Vaccination and Risk of Childhood IgA Vasculitis. Pediatrics, 2018, 142, .	2.1	12
138	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2018, 70, 2077-2086.	5.6	12
139	Therapeutic plasma exchange in systemic vasculitis. Current Opinion in Rheumatology, 2012, 24, 261-266.	4.3	11
140	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open, 2022, 12, e050507.	1.9	11
141	Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). Frontiers in Medicine, 2021, 8, 732934.	2.6	10
142	Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses. Rheumatology, 2011, 50, 1099-1105.	1.9	9
143	Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. Clinical and Experimental Rheumatology, 2016, 34, S89-92.	0.8	8
144	L47. Single-organ vasculitis: Conceptual and practical considerations. Presse Medicale, 2013, 42, 628-634.	1.9	6

#	Article	IF	Citations
145	Vocal fold bamboo nodes in undifferentiated connective tissue disease. Rheumatology, 2014, 53, 1993-1993.	1.9	6
146	Sweet syndrome revealing microscopic polyangiitis. Rheumatology, 2012, 51, 1916-1917.	1.9	5
147	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 1134-1138.	3.4	4
148	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.8	3
149	Impact of apremilast on quality of life in BehÃ§etâ€™s syndrome: analysis of the phase 3 RELIEF study. RMD Open, 2022, 8, e002235.	3.8	3
150	Incidence of giant cell arteritis in six districts of Paris, France (2015â€“2017). Rheumatology International, 2022, 42, 1721-1728.	3.0	3
151	New horizons for treatment of ANCA-associated vasculitides. Rheumatology, 2012, 51, 583-584.	1.9	2
152	Blue toe syndrome in cutaneous polyarteritis nodosa. Rheumatology, 2018, 57, 1281-1281.	1.9	2
153	THU0286â€…MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
154	Classification and epidemiology of vasculitis. , 2015, , 1271-1279.e1.		2
155	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. Seminars in Arthritis and Rheumatism, 2022, 55, 152021.	3.4	2
156	FRI0283â€…PRESENTATION AND MANAGEMENT OF GIANT CELL ARTERITIS IN A REAL-WORLD SETTING (ARTEMIS) Tj ETQq0 0 0 rgBT /O		1
157	FRI0284â€…RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
158	Case 36-2003: A Woman with Impaired Renal Function. New England Journal of Medicine, 2004, 350, 1058-1058.	27.0	0
159	INTERNATIONAL CONSENSUS PROJECT: NEURO-BEHCET DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.69-e4.	1.9	0
160	Reply. Arthritis and Rheumatology, 2015, 67, 1408-1408.	5.6	0
161	Reply to: â€œThe relationship between lymphocytic thrombophilic arteritis and cutaneous polyarteritis nodosaâ€• Journal of the American Academy of Dermatology, 2016, 75, e245-e246.	1.2	0
162	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. Rheumatology, 2020, 59, 1187-1187.	1.9	0

#	Article	IF	Citations
163	Leptospirosis Followed by Kawasaki-Like Disease: Case Report From an Adult Swiss Patient and Review of the Literature. Open Forum Infectious Diseases, 2021, 8, ofab088.	0.9	0